fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Non Banking Mergers & Acquisitions

New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

Solvias expands testing solutions to support development of safe and effective advanced therapies

Ritu M R by Ritu M R
July 13, 2022
in Mergers & Acquisitions, Healthcare, The Global Economics, Top Stories
Reading Time: 3 mins read
0
New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

32
SHARES
178
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

Solvias, one of the world’s leading independent pharmaceutical, biotech and medical device industries, announced on Tuesday that it acquired Utrecht, Netherlands-based Cergentis. The acquisition strengthens Solvias platform of biologics and cell & gene therapy (CGT) testing solutions.

According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are expected to accelerate at a 63 percent compound annual growth rate (CAGR) through 2026. As more researchers hold on to emerging genetic engineering techniques to develop complex, novel medicines, they require sophisticated solutions to examine their well-being and efficiency.

With the inclusion of Cergentis, Solvias supports the rolling number of global pharmaceutical, biotech, manufacturing, and contract development organizations developing genetically engineered therapies with an extended platform of testing services emphasised by:

  • An extremely scientific team holding advanced degrees and profound expertise immersed in developing genome techniques and evolving regulatory requirements.
  • proprietary genomic analysis technology that delivers comprehensive data in a single experiment that allows effective decision-making and R&D program design
  • a global network serving customers across three continents
  • personalised support for separate genetic engineering applications, including cell and gene therapy, cell line development & genetically engineered models
  • specialized knowledge in genomic sequencing of early-stage cell positions to support one of the first steps in the R&D process
  • high-touch support encompassing end-to-end digital project management, logistical services, and reporting capabilities to enable swift turnaround time.

The Chief Executive Officer at Solvias, Archie Cullen stated that the company has relentlessly focused on ensuring the safety of new therapies in development. Cergentis is a foundation for acquisition with their solutions supporting complex and emerging therapies. He added that they would continue to pursue strategic acquisitions that add specialized capabilities to their offering and advance their goal of being a forerunner in the pharmaceutical manufacturing industry.

Joris Schuurmans, the Chief Executive Officer of Cergentis added that they were excited to be a part of a global leader that complements their scientific expertise, customer service and innovation. The two companies share a deep commitment to provide customers with the highest quality solutions and support to ensure that their products safely reach the people who need them the most.

Joris Schuurmans will join the Solvias leadership team and continue to lead operations for Cergentis, with immediate effect.

Cergentis marks Solvias’ second acquisition since associating with health care investors Water Street Healthcare Partners and JLL Partners in 2020.The company has enlisted business leaders to join its board and started a program to notably expand and upgrade its information technology platform and infrastructure to support its plans for international expansion.

About Cergentis

Cergentis is a trusted genomics-focused biotechnology company providing in-house solutions and services based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research organizations. With widely recognized and published genetic analyses, the company harnesses a global customer base in the QC and characterization of genetically engineered models, biopharmaceutical cell line development, and cell- and gene therapy products. By serving to eliminate risk of minimizing time-to-clinic, R&D program decisions, supporting patient safety and providing objective genomic evidence for regulators, Cergentis aims to support biopharmaceutical medicine development programs globally.

About Solvias AG

 Solvias is a global leader in manufacturing, pharmaceutical, biotech, contract research, development and for material science and cosmetic industries. Leveraging on twenty years of scientific expertise, Solvias delivers scalable and flexible  manufacturing and analytical solutions that ensure the sustainability of pharmaceutical and medical device products across their life cycle. Solvias is headquartered in Kaiseraugst near Basel, Switzerland, and its laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA guidelines.

Via: short URL
Tags: CergentishealthcareM&ApharmaceuticalsSolvias
Ritu M R

Ritu M R

Ritu is a professional who aims at writing informative and engaging articles that appeal to the readers.

Related Posts

Sri Lanka: IMF approves $3 billion bailout for a crisis-stricken economy
Economy

Sri Lanka: IMF approves $3 billion bailout for a crisis-stricken economy

by Riya Thomas
March 21, 2023
First Republic Shares Plummet Amid Liquidity Fears
Banking

First Republic Shares Plummet Amid Liquidity Fears

by Anuj Singh
March 21, 2023
Amazon Announces Second Round of Layoffs, 9000 Roles to be Terminated
Technology

Amazon Announces Second Round of Layoffs, 9000 Roles to be Terminated

by Rahil Adnan
March 21, 2023
UEM Edgenta Paves the Way for Non-Clinical Tech Companies To Improve Healthcare Services
Exclusive Coverage

UEM Edgenta Paves the Way for Non-Clinical Tech Companies To Improve Healthcare Services

by The Global Economics
March 21, 2023
Saudi Real Estate Refinance Company (SRC) mulls its largest refining deal worth $1.3bn with Alrajhi
Islamic

Saudi Real Estate Refinance Company (SRC) mulls its largest refining deal worth $1.3bn with Alrajhi

by Riya Thomas
March 20, 2023
Previous
Next
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

First Republic Shares Plummet Amid Liquidity Fears

First Republic Shares Plummet Amid Liquidity Fears

March 21, 2023
Sri Lanka: IMF approves $3 billion bailout for a crisis-stricken economy

Sri Lanka: IMF approves $3 billion bailout for a crisis-stricken economy

March 21, 2023
Amazon Announces Second Round of Layoffs, 9000 Roles to be Terminated

Amazon Announces Second Round of Layoffs, 9000 Roles to be Terminated

March 21, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version